GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Werewolf Therapeutics Inc (NAS:HOWL) » Definitions » Median PS Value

Werewolf Therapeutics (Werewolf Therapeutics) Median PS Value : $0.00 (As of Jun. 08, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Werewolf Therapeutics Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Werewolf Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.451. Werewolf Therapeutics's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2024-06-08), Werewolf Therapeutics's share price is $3.49. Werewolf Therapeutics's Median PS Value is $0.00. Therefore, Werewolf Therapeutics's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Werewolf Therapeutics's Median PS Value or its related term are showing as below:

HOWL's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.68
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Werewolf Therapeutics Median PS Value Historical Data

The historical data trend for Werewolf Therapeutics's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Werewolf Therapeutics Median PS Value Chart

Werewolf Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
- - - - -

Werewolf Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Werewolf Therapeutics's Median PS Value

For the Biotechnology subindustry, Werewolf Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Werewolf Therapeutics's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Werewolf Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Werewolf Therapeutics's Price-to-Median-PS-Value falls into.



Werewolf Therapeutics Median PS Value Calculation

Werewolf Therapeutics's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.451*0
=0.00

10-Year Median PS Ratio is 0.
Werewolf Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.451.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Werewolf Therapeutics  (NAS:HOWL) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Werewolf Therapeutics's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=3.49/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Werewolf Therapeutics Median PS Value Related Terms

Thank you for viewing the detailed overview of Werewolf Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Werewolf Therapeutics (Werewolf Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
200 Talcott Avenue, 2nd Floor, Watertown, MA, USA, 02472
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.
Executives
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Luke Evnin director THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116
Meeta Chatterjee director C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Michael A. Sherman director 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Chulani Karunatilake officer: Chief Technology Officer 1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Reid Leonard officer: Chief Operating Officer 1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Mpm Oncology Innovations Fund Lp 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Longwood Fund Iii Gp, Llc 10 percent owner 800 BOYLSTON ST, SUITE 1555, BOSTON MA 02199
Derek Dirocco director 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Moshe Arkin 10 percent owner 6 HACHOSHLIM ST., HERZELIA L3 4672406
Alon Lazarus director, 10 percent owner C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Daniel J Hicklin director, 10 percent owner, officer: See Remarks
Sphera Funds Management Ltd. 10 percent owner 4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Management Lp 10 percent owner 4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Gp Ltd. 10 percent owner 4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520

Werewolf Therapeutics (Werewolf Therapeutics) Headlines